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Protein phosphatase 2A (PP2A) is a serine/threonine phosphatase that is a primary regula-
tor of cellular proliferation through targeting of proliferative kinases, cell cycle regulators,
and apoptosis inhibitors. It is through the regulation of these regulatory elements that gives
PP2A tumor suppressor functions. In addition to mutations on the regulatory subunits,
the phosphatase/tumor suppressing activity of PP2A is also inhibited in several cancer
types due to overexpression or modification of the endogenous PP2A inhibitors such
as SET/I2PP2A. This review focuses on the current literature regarding the interactions
between the lipid signaling molecules, selectively sphingolipids, and the PP2A inhibitor
SET for the regulation of PP2A, and the therapeutic potential of sphingolipids as PP2A
activators for tumor suppression via targeting SET oncoprotein.
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INTRODUCTION
Protein phosphatase 2A (PP2A) is a serine/threonine phosphatase,
which serves as a regulator of cell death and/or cell division, func-
tions performed by targeting kinases and other effectors of these
processes including Bcl-2 and the Aurora kinases (1–3). In non-
malignant cells, PP2A restrains cell division to occur only when
necessary stimuli is present, and induces cell death by triggering
extrinsic or intrinsic death signals.
Structurally, PP2A is a holoenzyme, which typically contains
a catalytic “C” subunit, coupled with an “A” scaffolding subunit,
and a regulatory “B” subunit (Figure 1A) (4). Some form of PP2A
holoenzyme is found in all tissues with variations of the subunit
isoforms and/or post-translational modification of the subunits
accounting for tissue specificity, subcellular distribution, and sub-
strate selection. In this article, we focused on one of the major
cancer-related PP2A inhibitors, SET, and its regulation by sphin-
golipids, primarily ceramide for PP2A reactivation and tumor
suppression.
PP2A AS A TUMOR SUPPRESSOR
Protein phosphatase 2A was first identified as a tumor suppres-
sor when it was discovered that the known carcinogen okadaic
acid is a specific PP2A inhibitor (5–7). Similarly, the transforming
(oncogenic) simian vacuolating virus 40 (SV40) small T-antigen
is believed to be tumorigenic due to PP2A inhibition (8). Like-
wise, PP2A activity was inhibited in a variety of cancers including
chronic myeloid leukemia (CML), acute myeloid leukemia (AML),
polycythemia vera (PV), and lung cancer (9–12). Importantly,
reactivation of PP2A through genetic or pharmacologic means
induces cell death in various cancer cells in culture and in animal
models.
BIOLOGICAL INHIBITORS OF PP2A
Protein phosphatase 2A can be regulated through changes in
phosphatase activity as well as changes in substrate specificity, the
latter of which is primarily controlled by the regulatory B subunits.
The B subunits are often tissue-specific and mediate subcellular
localization of the holoenzyme. The catalytic activity is controlled
by post-translational modification of the C-subunit and through
endogenous inhibitory proteins. Although the specific interplay
between each of these inhibitory proteins and the PP2A holoen-
zyme is not fully understood, they are typically found together in
a complex suggesting a role for direct inhibition.
I1PP2A
One of these endogenous inhibitors is Inhibitor 1 of PP2A
(I1PP2A, also known as acidic leucine-rich nuclear phos-
phoprotein 32 A or ANP32A) (13). I1PP2A (ANP32A) is a
sphingosine/dimethylsphingosine-sensitive PP2A inhibitor that
regulates PP2A function in human umbilical vein endothelia cells
(HUVEC) (14). I1PP2A also functions as part of the histone
acetyltransferase regulatory INHAT complex. Another member of
the ANP32 family, ANP32e (formerly cerebellar developmental-
regulated protein 1, CPD1), is a PP2A inhibitor and also plays a
role in neuronal development (15, 16).
CIP2A
Cancerous Inhibitor of PP2A (CIP2A) was first described as a
fusion protein detected in a leukemia patient (17), which is an
endogenous PP2A inhibitor that has been shown to have both
proto-oncogenic and prognostic value in cancer. CIP2A is over-
expressed in several different cancer types including head and
neck squamous cell carcinoma (HNSCC), colon-cancer and CML
(18), a subset of myleodysplasic syndromes (19), and osteosar-
coma (20) as well as others (21). CIP2A also serves as a prognostic
marker in cutaneous malignant melanoma (CMM) (22), cholan-
giocarcinoma (23),pancreatic ductal adenocarcinoma (PDA) (24),
aggressive astrocytoma (25), and others (26, 27). Physiologi-
cally, CIP2A is particularly important for shielding c-Myc from
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FIGURE 1 | Organization of PP2A holoenzyme with/without
SET/I2PP2A interaction. (A)The PP2A holoenzyme consists of a
scaffolding “A,” regulatory “B,” and catalytic “C” subunit. Each subunit type
can include any one of multiple species for each subunit. (B) SET inhibits
PP2A activity through direct interaction within the catalytic domain of PP2A.
dephosphorylation by PP2A, leading to protection of c-Myc from
proteasomal degradation (28).
SET/I2PP2A
Inhibitor 2 of PP2A (I2PP2A/SET also known as TAF-1β) is
an endogenous PP2A inhibitor and a well-described proto-
oncoprotein. Although the specific mechanism by which SET
inhibits PP2A is believed to be through direct binding to the
catalytic domain of PP2A (Figure 1B), the details of this inter-
action have yet to described. Similar to CIP2A, SET plays a role
in a variety of cancers (29, 30) and was originally discovered as
a chimeric protein (31). A fusion protein consisting of the entire
SET protein sequence coupled with the carboxyl-terminal end of
the CAN nuclear pore protein was found in a single acute lympho-
cytic leukemia patient sample and postulated to be an oncogene
(32, 33). Mechanistically, SET inhibits PP2A in cell-free assays
at low (nanometer) concentrations while not inhibiting related
phosphatases (34). Since its discovery, SET has been found to be
involved in a variety of cancers, primarily as an inhibitor of PP2A.
Specifically, there are three described mechanisms by which SET
has been shown to become an active PP2A inhibitor: (i) overex-
pression of SET is detected in several leukemias, Wilms tumors
(9, 29), epithelial ovarian cancer (35), prostate cancer (36), and
lung cancer (12); (ii) altered phosphorylation of SET was observed
in prostate cancer, PV, Alzheimer’s disease, and in activated T-
cells with the suspected kinases defined as PKC, casein kinase II,
and PKD, respectively. PI3K is also suspected of phosphorylating
SET for activation (11, 36–39); and (iii) changes in endogenous
ceramide (an inhibitor of SET, discussed below) are also common
in several cancers, reviewed in Ref. (40). Independent of PP2A
inhibitory function, SET also functions to regulate gene expression
through alteration of histone acetylation (41, 42).
Several of the domains of the SET protein have been attributed
to specific functions. An internal span close to the N-terminus
(residues 36–124) has been found to be critical for PP2A inhibitory
function (43). Conversely, the C-terminal end is responsible for
histone binding (44). Additional published data demonstrate that
both the N- and C-terminus segments of granzyme A (45) cleaved
SET at N175 to bind and inhibit PP2A (46). The coiled-coil domain
(E25-Q65) is critical for SET dimerization, which modulates some,
but not all, of the nuclear functions of SET. Dimerization is not
necessary for SET to inhibit PP2A (47). Interestingly, the structural
details of specific interactions between SET and the PP2A holoen-
zyme with specific A, B, and C subunits with tumor suppressor
functions have not yet been described.
SET REGULATION IN HUMAN CANCERS
Overexpression of SET is found in CML, Wilms tumors, and
in lung cancers. In CML, an increase in heterogeneous nuclear
ribonucleoprotein A1 (hnRNP A1) leads to an enhanced mRNA
stability, which produces an increase in SET protein levels (9).
Knock-down of SET in both CML cell lines as well as CML CD34+
primary patient samples restored PP2A activity indicating a causal
role for SET in PP2A inhibition in these cells. Additionally, CML
cells expressing SET knock-down had reduced BCR/ABL1 phos-
phorylation (activity) as well as reduced clonogenic potential. SET
was also found to be overexpressed in lung tumors when com-
pared to normal lung tissue with an accompanying increase in
PP2A phosphorylation (inhibition) (12). Knock-down of SET in
A549 lung cancer cells produced an increase in PP2A activity and
a reduction in tumor proliferation in situ and in SCID mice. SET
was found overexpressed in B-CLL cells as well as in the immortal,
non-CLL B-cell cell lines, Raji and Ramos (48). Reactivation of
PP2A through SET knock-down using shRNAs or a SET-targeting
peptide induced cytotoxicity in both Raji and Ramos cells (48).
TARGETING SET BY SPHINGOLIPIDS FOR TUMOR
SUPPRESSION
Ceramides are a class of sphingolipids consisting of a sphingosine
backbone, which is N-acylated and joined to a fatty acid moiety
(Figure 2). Ceramide can be generated de novo through a series of
steps starting with serine palmitoyltransferase (SPT), which uses
acetyl-CoA and serine to form 3-keto-dihydrosphingosine. This
product is desaturated by dihydrosphingosine desaturase (DES)
to produce dihydrosphingosine, which is the acylated by ceramide
synthase (CerS1-6) to form ceramide with the desaturation reac-
tion by dihydroceramide desaturase. Alternative pathways of syn-
thesis of ceramide are through the breakdown of sphingomyelin
by sphingomyelinases or originating directly from sphingosine
produced by the dephosphorylation of sphingosine-1-phosphate
(S1P) via the salvage pathway involving CerS function (Figure 2).
Ceramide was shown to activate PP2A (49–51), as well as the
related phosphatase PP2C (52), without any mechanistic infor-
mation. Recent data provided a unique mechanism for ceramide-
mediated PP2A activation, revealing that ceramide directly binds
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FIGURE 2 | Generation of ceramide and FTY720-P. Ceramide can
be generated through de novo synthesis originating with
palmitoyl-CoA and serine, though the hydrolysis of sphingomyelin or
through the “salvage pathway” via the acetylation of sphingosine.
FTY720, a sphingosine (myriocin) analog, is phosphorylated by SphK
(mainly by Sphk2 in the nucleus).
SET, relieving PP2A from SET, increasing PP2A activity, leading
to tumor suppression, consistent with anti-proliferative roles of
ceramide (48–52).
FTY720 (fingolimod, Gilenya, Novartis) is a synthetic sphin-
gosine (myriocin) analog currently approved for the treatment of
multiple sclerosis. Originally designed as an immunosuppressant,
FTY720 is given orally as a pro-drug. Once internalized within
a target cell, FTY720 is mainly phosphorylated by sphingosine
kinase 2 (SphK2), producing FTY720-P. Following phosphoryla-
tion, FTY720-P is exported out of the cell, where it functions in
an autocrine/paracrine manner by binding to the sphingosine-1-
phosphate receptor 1 (S1PR1). Following binding to S1PR (except
S1PR2), the receptor is internalized and degraded, leading to
immune suppression. Thus FTY720-P is a functional antago-
nist for S1PR1. FTY720 was found to activate PP2A by Nagahara
et al. in HL-60RG and Jurkat cells (53). As a sphingosine analog,
FTY720 retains many of the functional characteristics of natural
sphingolipids, but it has a good bioavailability and a protracted
half-life (54).
REGULATION OF SET/PP2A INTERACTION BY CERAMIDE
AND FTY720
While SET can be regulated through expression levels or phospho-
rylation changes, the inhibitory properties of SET are also con-
trolled through sphingolipid signaling. While sphingolipids have
been shown to bind another PP2A inhibitor, I1PP2A/ANP32A,
SET is unique in that it contains a binding “pocket,” which affords
high affinity and substrate selectivity for ceramide.
Ceramide was described as a PP2A activator in 1993 (49) and,
although there has been evidence of an interaction between PP2Ac
and ceramide (55), an alternative mechanism by which ceramide
activates PP2A is likely through direct binding to SET.
In fact, SET was found to be a direct target of ceramide by
Mukhopadhyay et al. by employing biotin-labeled C6-ceramide to
pull-down ceramide associated proteins found in A549 lung car-
cinoma cell extracts using avidin-conjugated columns (56). The
prominent protein found through SDS-PAGE was excised and
identified though LC/MS as SET. Further examination helped
identify that different species of ceramide had vastly different
binding affinities for SET. First, using recombinant SET pro-
tein, our laboratory found that only the natural isomer, D-e-
C6-ceramide, and not L-e-C6-ceramide binds SET. Additionally,
de novo-generated biotin-labeled C18-ceramide, but not C16-
ceramide, bound to SET following an avidin pull-down. Moreover,
purified trimeric PP2A supplemented with recombinant SET was
activated by the addition of water-soluble pyridinium (Pyr) D-
e-C6-ceramide, while its isomers Pyr-dihydro-C6-ceramide, Pyr-
L-e-C6-ceramide, Pyr-D-theo-C6-ceramide, or Pyr-D-theo-C6-
ceramide produced no PP2A activation. Taken together, these data
indicate that ceramide functions as a PP2A activator through, at
least in part, the binding to SET.
This attribute of ceramide selectivity for SET binding led to
the construction of a molecular model wherein ceramide could be
docked and specific interactions were predicted. Using computa-
tional modeling, a hydrophobic pocket within the SET protein
was identified as the expected site for ceramide binding. This
pocket includes the residue K209 on helix 7, which was predicted
through in silico modeling to be significant for ceramide bind-
ing. When mutated to K209D (replacing the positively charged
R-group of lysine with the negatively charged group of aspartate),
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the ability of ceramide to bind SET was decreased by>75%. More-
over, ceramide-mediated PP2A activation induced proteasomal
degradation of c-Myc, and tumor suppression (56).
Additional work, which demonstrates the binding of ceramide
to SET, expanded on the interactions between ceramide and SET
but also ascertained the mechanism of action of the PP2A acti-
vator/synthetic sphingolipid analog FTY720 (12). Data indicated
preferential binding of C18-ceramide over C16-ceramide to SET.
Indeed, C18-ceramide had the highest affinity for wild-type SET,
although lesser affinity ceramides were also found to bind SET
including C20-, C22-, C26-ceramides, and minute binding of C24-
ceramide. Moreover, in addition to the K209 residue (56), Y122
was suspected to interact with K209 via a hydrophobic/ionic inter-
action. The Y122C mutant of SET was employed to determine
the potential role of opening the “gate” produced through the
K209/Y122 interaction with ceramide. The Y122C mutant bound
to all ceramides. More importantly, by using a SET mutant, which
is retained within the endoplasmic reticulum (ER) rather than
the nucleus, the ER-targeted SET demonstrated high affinity for
C16- rather than C18-ceramide despite the higher concentration
of C16-ceramide in both compartments (12).
When compared to normal lung tissue, an increase in SET pro-
tein levels as well as a corresponding decrease in C18-ceramide
were detected, indicating a two-pronged reduction in PP2A activ-
ity through both an increase in SET and a decrease in the SET
inhibitor C18-ceramide. Moreover, mRNA levels of ceramide syn-
thase 1 (CerS1), which is responsible for the generation of C18-
ceramide were decreased in lung tumor tissue compared to normal
lung tissue. Interestingly, the mRNA of CerS6 and its product,
C16-ceramide were both increased in lung tumor tissue (12).
FTY720 REACTIVATES PP2A
The structural and functional similarities of the synthetic sphin-
golipid analog FTY720 (myriocin analog) suggest that it too, may
be a ligand for SET. In silico, molecular docking experiments indi-
cated that the binding of FTY720, but not FTY720-P, to SET is
favorable and employs the same K209 residue as ceramide. Indeed,
using a combination of LC/MS, surface plasma resonance (SPR)
and biotin-tagged FTY720 pull-downs FTY720, but not immuno-
suppressive FTY720-P, was found to bind directly to SET (12).
Similar to the findings with ceramide, the K209D mutant SET
did not bind FTY720 with the high affinity when compared to
wild-type SET (12). These studies suggested that FTY720 and
not immune suppressive FTY720-P exerts anti-cancer activities
against various cancer types. Interestingly, FTY720-P was shown to
inhibit colitis-mediated colon-cancer growth/proliferation (57).
However, whether PP2A reactivation was involved in the sup-
pression of colitis-mediated colon tumor growth/proliferation by
FTY720-P, which appeared to be phosphorylated by tumor SphK1
in SphK2−/−mice, has not been examined.
FTY720 has favorable pharmacokinetic properties compared
to natural ceramides, therefore Saddoughi et al. used FTY720 as
a therapeutic drug for the treatment of A549 lung cancer cell-
derived tumors. Interestingly, both FTY720 and SET knock-down
prevented the growth of A549 in situ and in vivo. Surprisingly,
through the use of caspase 3/7 knockout MEFs and the caspase
inhibitor Z-VAD, FTY720-induced cell death was found to be
caspase-independent (12). Further experiments using receptor-
interacting serine/threonine-protein kinase 1 (RIP1) knockout
cells, siRNA, or chemical inhibitor of RIPK1 (necrostatin) helped
determine the cell death induced by FTY720 in A549 cells to
be a caspase-independent, RIP1-dependent programed necrosis
known as necroptosis (12).
Prior to the quantitation of SET levels in CLL by Christensen
et al. (48), Liu et al. found therapeutic potential in admin-
istering FTY720 to primary CD19+ lymphocytes from B-CLL
patients (58). Likewise, several cell lines were found to be sen-
sitive to FTY720; MEC-1 B-CLL derived cells, Ramos and Raji
cells (described above), and the acute lymphoblastic leukemia cell
lines 697 and RS4;11. While SET was not examined in this study,
PP2A was found to be activated by FTY720 and re-inhibition
of PP2A with okadaic acid rescued cells from FTY720-mediated
cytotoxicity. While the cytotoxic effects of FTY720 were found to
be PP2A-dependent, the primary receptor involved in FTY720-
induced immunosuppression, the S1PR1, was found to be not
involved (48).
Similarly, Oaks et al. found that targeting SET with FTY720 was
able to selectively kill hematopoietic progenitor cells expressing the
oncogenic Jak2V617F tyrosine kinase (11). Again, FTY720-P was
found to be ineffective in activating PP2A. While cells expressing
Jak2V617F did not exhibit increased SET expression, serine phos-
phorylation of SET was found to require Jak2 activity. Indeed,
phosphorylation of SET on the serine 9 residue was necessary for
complete PP2A inhibition, consistent with data obtained in other
models (37).
CERAMIDE AND FTY720-MEDIATED PP2A ACTIVATION
LEADS TO TUMOR SUPPRESSION
Mukhopadhyay et al. have found that synthetic C6-ceramide is a
viable treatment for prostate cancer cells, which overexpress the
SET protein (59). When compared to normal prostate epithe-
lium, the androgen-resistant prostate cancer cell lines PC-3 and
DU145, as well as the androgen-sensitive LNCaP cell line were all
found to have elevated SET levels. Likewise, c-Myc was also over-
expressed in all of the prostate cancer cells compared to the normal
prostate tissue. While total PP2Ac levels were consistent between
the cancer and non-cancerous cell lines, PP2Ac phosphorylation at
tyrosine 307 was higher in cancer cell lines indicating that the PP2A
was inactive. Ceramide levels were examined in these cells, and it
was found to induce apoptosis (60), a known activator of PP2A
(49) and a direct inhibitor of SET (56). Therefore, endogenous
ceramide levels were measured in cancerous PC-3 and LNCaP
cells and compared to normal prostate epithelium. The PC-3 cells
were found to have elevated C20-ceramide and a decrease in C14-,
C16-, C18-, C22-, C24-, and C26-ceramides. The LNCaP cells had an
elevated C16-, C18-, and C20- and lower levels of C14, C22-, C24-,
and C26-ceramides.
To increase ceramide levels, synthetic C6-ceramide was given at
concentrations ranging from 5 to 40µM and cell viability assayed
24 and 48-h post-treatment (59). While normal prostate epithe-
lium as unaffected at any dose or time point, all three prostate
cancer cell lines showed a dose- and time-dependent cell death.
Importantly, treatment with C6-ceramide (10µM, 48 h) reduced
c-Myc levels in each of the cancer cell lines. Moreover,pretreatment
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FIGURE 3 | Roles of SET/I2PP2A and ceramide/FTY720 on
PP2A-dependent regulation of cell death. PP2A inhibition is inhibited
through various mechanisms in cancer via an increase in SET expression as
well as altered phosphorylation of SET. Targeting SET by ceramide and/or
FTY720 inhibits SET, activates PP2A, and induces cell death in various
cancer cells.
with the PP2A inhibitor okadaic acid (10 nM) increased basal
c-Myc levels and prevented a decrease following treatment with
C6-ceramide (10µM, 48 h).
Recently, Chen et al. found that treating AML-ETO+ cell
lines with FTY720-induced caspase-depended apoptosis through
a PP2A-dependent pathway (61). To unravel the mechanisms
involved in FTY720-induced cell death in these cells, the authors
performed gene microarray analyses. Among the genes found to
be upregulated by FTY720 were acid sphingomyelinase, acid beta-
glucosidase and sphingolipid delta(4)-desaturase, all of which
are involved in the regulation of ceramide metabolism. Fur-
ther study using qPCR found another ceramide-generating gene,
neutral sphingomyelinase 2 (nSmase2) to be upregulated with
FTY720 treatment. Accordingly, using high-performance liquid
chromatography–electrospray ionization tandem mass spectrom-
etry (HPLC-ESI-MS/MS), the authors found an increase in
ceramide levels in FTY720-treated Kasumi-1 cells. In particular,
C18-, C20-, and C22-ceramides were increased in a time (4–6 h) and
dose (7.5–10µM)-dependent manner. Particularly, these same
ceramides were enriched in the mitochondrial fraction of FTY720-
treated cells with C22-ceramide showing a dominant increase.
Intriguingly, sphingosine-1-phosphate (S1P), a known inhibitor
of PP2A activity (11), was found to be decreased following FTY720
treatment. Accordingly, ceramide synthase inhibitor fumonisin B1
(FB1) and the neutral sphingomyelinase inhibitor GW4869 par-
tially protected Kasumi-1 cells from apoptosis following FTY720
treatment (61).
CONCLUSION
Protein phosphatase 2A is commonly deregulated in cancers, typ-
ically due to inhibition by SET. The protein level of SET can be
increased or SET can be subject to post-translational modification
through a variety of oncogenic pathways, each resulting in the
inhibition of PP2A activity (Figure 3). The commonality of PP2A
inhibition by SET oncoprotein, which is overexpressed in various
tumor tissues compared to non-cancerous tissue counterparts,
makes SET a promising target for cancer therapeutics. Previously,
most of the research on PP2A used ceramide as tool for activation.
The recent data (12) provide us with the groundwork for under-
standing the biological properties of both ceramide/FTY720 and
PP2A. Our knowledge of the relationship between sphingolipids
and PP2A has been greatly enhanced through the employment
of mass spectrometry, which allows for identification of spe-
cific lipids and lipid species, as well as computational modeling
of SET to estimate the interactions between ceramide/FTY720
and SET. The use of sphingolipids and, synthetic sphingolipid
analogs, or newly developed SET inhibitors, as cancer therapeu-
tics is likely to increase as we are better able to target SET to
reactivate PP2A, leading to tumor suppression. We believe that
structural studies coupled with studies to identify the mechanism
by which ceramide/SET binding regulates tumor suppressor PP2A
will lead to the development of novel SET inhibitors with improved
anti-cancer activity without immune suppression and other toxic
effects.
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